{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T21:15:25Z","timestamp":1649106925153},"reference-count":25,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2022,1,29]]},"DOI":"10.1536\/ihj.21-475","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T22:11:28Z","timestamp":1643407888000},"page":"153-158","source":"Crossref","is-referenced-by-count":0,"title":["Antiphospholipid Syndrome Diagnosed as a Result of the Occurrence of an Ischemic Stroke After a Successful Catheter Ablation of Atrial Fibrillation and Continuous Direct Oral Anticoagulants"],"prefix":"10.1536","volume":"63","author":[{"given":"Yumiko","family":"Haraguchi","sequence":"first","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuho","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehito","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Minami","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Naito","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. Eur Heart J 2016; 37: 2478-87.","DOI":"10.1093\/eurheartj\/ehw087"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Saglietto A, De Ponti R, Di Biase L, <i>et al<\/i>. Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: A meta-analysis. J Cardiovasc Electrophysiol 2020; 31: 1040-7.","DOI":"10.1111\/jce.14429"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Calkins H, Hindricks G, Cappato R, <i>et al<\/i>. 2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018; 20: e1-e160.","DOI":"10.1093\/europace\/eux274"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Arai M, Okumura Y, Nagashima K, <i>et al<\/i>. Adverse Clinical Events during Long-Term Follow-Up After Catheter Ablation of Atrial Fibrillation. Int Heart J 2019; 60: 812-21.","DOI":"10.1536\/ihj.18-517"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72.","DOI":"10.1378\/chest.09-1584"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Finazzi G, Marchioli R, Brancaccio V, <i>et al<\/i>. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.","DOI":"10.1111\/j.1538-7836.2005.01340.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Crowther MA, Ginsberg JS, Julian J, <i>et al<\/i>. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.","DOI":"10.1056\/NEJMoa035241"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Huang S, Zhao T, Liu C, <i>et al<\/i>. Portable Device Improves the Detection of Atrial Fibrillation After Ablation. Int Heart J 2021; 62: 786-91.","DOI":"10.1536\/ihj.21-067"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Janse PA, van Belle YL, Theuns DA, Rivero-Ayerza M, Scholten MF, Jordaens LJ. Symptoms versus objective rhythm monitoring in patients with paroxysmal atrial fibrillation undergoing pulmonary vein isolation. Eur J Cardiovasc Nurs 2008; 7: 147-51.","DOI":"10.1016\/j.ejcnurse.2007.08.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev 2017; 31: 406-17.","DOI":"10.1016\/j.blre.2017.07.006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke 2005; 36: 592-6.","DOI":"10.1161\/01.STR.0000154858.27353.df"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 2007; 66: 927-30.","DOI":"10.1136\/ard.2006.067314"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Cervera R, Tektonidou MG, Espinosa G, <i>et al<\/i>. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus 2011; 20: 174-81.","DOI":"10.1177\/0961203310395052"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Samejima Y, Kodaka M, Ichikawa J, <i>et al<\/i>. Management of a Patient With Antiphospholipid Syndrome Undergoing Aortic Valve Replacement Using the Hepcon Hemostasis Management System Plus and Rotational Thromboelastometry: A Case Report. A &amp; A Case Reports 2017; 8: 100-4.","DOI":"10.1213\/XAA.0000000000000439"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Koniari I, Siminelakis SN, Baikoussis NG, Papadopoulos G, Goudevenos J, Apostolakis E. Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. J Cardiothorac Surg 2010; 5: 101.","DOI":"10.1186\/1749-8090-5-101"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yoshinaga K, Otsuka Y, Furukawa T, Amitani S, Kimura N, Sanui M. Correlation between activated clotting time monitoring and heparin concentration measurement in a patient with antiphospholipid syndrome during cardiac valve surgery: a case report. JA Clin Rep 2021; 7: 24.","DOI":"10.1186\/s40981-021-00427-x"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Gaita F, Caponi D, Pianelli M, <i>et al<\/i>. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010; 122: 1667-73.","DOI":"10.1161\/CIRCULATIONAHA.110.937953"},{"key":"18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/europace\/eus329","volume":"15","year":"2013","unstructured":"18. Martinek M, Sigmund E, Lemes C, <i>et al<\/i>. Asymptomatic cerebral lesions during pulmonary vein isolation under uninterrupted oral anticoagulation. Europace 2013; 15: 325-31.","journal-title":"Europace","ISSN":"http:\/\/id.crossref.org\/issn\/1099-5129","issn-type":"print"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Nakamura K, Sasaki T, Take Y, <i>et al<\/i>. Impact of the type of electroanatomic mapping system on the incidence of cerebral embolism after radiofrequency catheter ablation of left atrial tachycardias. Heart Rhythm 2020; 17: 250-7.","DOI":"10.1016\/j.hrthm.2019.09.009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nakamura K, Sasaki T, Take Y, <i>et al<\/i>. Incidence and characteristics of silent cerebral embolisms after radiofrequency-based atrial fibrillation ablation: A propensity score-matched analysis between different mapping catheters and indices for guiding ablation. J Cardiovasc Electrophysiol 2020; 32: 16-26.","DOI":"10.1111\/jce.14800"},{"key":"21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.hrthm.2017.09.011","volume":"15","year":"2018","unstructured":"21. Cardoso R, Knijnik L, Bhonsale A, <i>et al<\/i>. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm 2018; 15: 107-15.","journal-title":"Heart Rhythm","ISSN":"http:\/\/id.crossref.org\/issn\/1547-5271","issn-type":"print"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Ruff CT, Giugliano RP, Braunwald E, <i>et al<\/i>. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62.","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J 2014; 78: 1997-2021.","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"24","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/MJT.0000000000001083","volume":"28","year":"2021","unstructured":"24. Kajy M, Mathew A, Ramappa P. Treatment Failures of Direct Oral Anticoagulants. American journal of therapeutics 2021; 28: e87-95.","journal-title":"American Journal of Therapeutics","ISSN":"http:\/\/id.crossref.org\/issn\/1075-2765","issn-type":"print"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Pengo V, Denas G, Zoppellaro G, <i>et al<\/i>. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132: 1365-71.","DOI":"10.1182\/blood-2018-04-848333"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/1\/63_21-475\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T03:43:53Z","timestamp":1643427833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/1\/63_21-475\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.21-475","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"article-number":"21-475"}}